71TiPA randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC/ETOP 1416-PEARLS)
Paz-Ares, L., Hasan, B., Dafni, U., Menis, J., De Maio, E., Oselin, K., Albert, I., Faehling, M., Van Schil, P., O'Brien, M.E.R.Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx085.013
Date:
April, 2017
File:
PDF, 39 KB
english, 2017
File converter
More search results
More benefits 
